KLTO
Klotho Neurosciences Inc
$
1.230
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.280
Open
1.270
VWAP
1.23
Vol
1.03M
Mkt Cap
39.97M
Low
1.220
Amount
1.27M
EV/EBITDA(TTM)
--
Total Shares
32.49M
EV
41.19M
EV/OCF(TTM)
--
P/S(TTM)
--
Klotho Neurosciences, Inc. develops essential medicines for the treatment of chronic diseases such as cancer, cardiovascular, and neurodegenerative disorders. The Company's licensed platforms, namely, a generic drug portfolio and a biosimilar biologics platform uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Its primary focus is the advancement of a sustainable portfolio of cell and gene therapy product candidates for age-associated neurologic diseases, both rare orphan diseases and diseases in larger patient populations. The Company's two lead gene therapy product candidates are KLTO-101 (AAV9-CMV-sKL) for the treatment or prevention of Alzheimer’s disease, and KLTO-202 (AAVmyo-Des-sKL) gene therapy product for the treatment and prevention of Lou Gehrig’s disease (amyotrophic lateral sclerosis).
Show More
Valuation Metrics
The current forward P/E ratio for Klotho Neurosciences Inc (KLTO.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Klotho Neurosciences Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2025Q1
YoY :
+136.14%
-1.59M
Operating Profit
FY2025Q1
YoY :
+232.42%
-2.23M
Net Income after Tax
FY2025Q1
YoY :
+100.00%
-0.08
EPS - Diluted
FY2025Q1
YoY :
+6970.20%
-1.55M
Free Cash Flow
FY2025Q1
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
KLTO News & Events
Events Timeline
2025-07-24 (ET)
2025-07-24
13:33:09
Klotho Neurosciences seeking to expand into adjacent technologies
2025-07-22 (ET)
2025-07-22
10:25:26
Klotho Neurosciences partners with AAVnerGene to make gene therapy assets
2025-07-16 (ET)
2025-07-16
06:02:43
Klotho Neurosciences regains compliance with Nasdaq
Sign Up For More Events
Sign Up For More Events
News
8.5
07-24NewsfilterPinnedKlotho Neurosciences, Inc. to Expand Development Programs Beyond Neurology
8.5
07-26Yahoo FinanceUPDATED: Klotho Neurosciences, Inc. to Expand Development Programs Beyond Neurology
7.5
07-23NASDAQ.COMKlotho Neurosciences Partners With AAVnerGene To Accelerate Cost-Effective Gene Therapy Development
Sign Up For More News
People Also Watch
ASNS
Actelis Networks Inc
0.531
USD
+1.14%
EONR
EON Resources Inc
0.332
USD
+3.10%
CJET
Chijet Motor Co Inc
2.620
USD
+1.16%
INTJ
Intelligent Group Ltd
1.218
USD
+1.08%
VRAX
Virax Biolabs Group Ltd
0.989
USD
-3.98%
CREV
Carbon Revolution PLC
4.910
USD
+42.32%
VISL
Vislink Technologies Inc
2.500
USD
0.00%
PMAX
Powell Max Ltd
0.410
USD
0.00%
CARV
Carver Bancorp Inc
2.500
USD
-1.96%
SOGP
Sound Group Inc
5.140
USD
-5.43%
FAQ
What is Klotho Neurosciences Inc (KLTO) stock price today?
The current price of KLTO is 1.23 USD — it has decreased -3.15 % in the last trading day.
What is Klotho Neurosciences Inc (KLTO)'s business?
What is the price predicton of KLTO Stock?
What is Klotho Neurosciences Inc (KLTO)'s revenue for the last quarter?
What is Klotho Neurosciences Inc (KLTO)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Klotho Neurosciences Inc (KLTO)'s fundamentals?
How many employees does Klotho Neurosciences Inc (KLTO). have?